An effective vaccine may be necessary to eliminate hepatitis C virus (HCV), but development has been hampered by several challenges including the variability of the virus and incomplete natural immunity, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo. One promising prime-boost viral vector vaccine is currently in clinical trials.
